Clinical Trial Results:
A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody response following three subcutaneous injections of CAD106
Summary
|
|
EudraCT number |
2005-000048-10 |
Trial protocol |
SE |
Global completion date |
17 Dec 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Feb 2017
|
First version publication date |
15 Feb 2017
|
Other versions |
|
Summary report(s) |
CCAD106A2101_NovCTR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.